The Artificial Intelligence in Pre-clinical Drug Development for AD/ADRD funding from the National Institutes of Health (NIH) supports research projects that apply existing or newly developed artificial intelligence (AI) and machine learning (ML) methods to various aspects of drug discovery and preclinical drug development to accelerate the identification, optimization, and selection of preclinical drug candidates for the treatment and prevention of Alzheimer’s disease (AD) and AD-related dementias (ADRD) and increase their likelihood of success during clinical drug development.

Funding Organization: National Institutes of Health (NIH), USA

Research Scope: Artificial intelligence (AI) and machine learning (ML)

Eligibility: Applications are open to researchers at research institutions in the USA and worldwide.

Maximum Award: The award provides up to 1 million USD per year for up to 5 years.

Application Process: Application should be submitted via the NIH ASSIST system.

Application Deadline: Letters of intent are due on 13 January 2025 and full applications are due on 13 February 2025.

Further information: https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-049.html